On November 15, 2023, Astellas Pharma shared a community letter with information on obtaining results for ASP0367 (MA-0211) in Pediatric Male patients with Duchenne muscular dystrophy.
Astellas’ Community Letter can be found by clicking here.
Astellas’ clinical trial study details can be found on their website.